The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events
Open accessAbstract
Objectives—: Non–high-density lipoprotein cholesterol (non-HDLC) levels reflect the full burden of cholesterol transported in atherogenic lipoproteins. Genetic studies suggest a causal association between elevated triglycerides (TGs)-rich lipoproteins and atherosclerosis. We evaluated associations between achieved non-HDLC and TG levels on changes in coronary atheroma volume. Approach and Results—: Data were analyzed from 9 clinical trials involving 4957 patients with coronary disease undergoing serial intravascular ultrasonography to assess changes in percent atheroma volume (ΔPAV) and were evaluated against on-treatment non-HDLC and TG levels. The effects of lower (<100 mg/dL) versus higher (≥100 mg/dL) achieved non-HDLC levels and lower (<200 mg/dL) versus higher (≥200 mg/dL) achieved TG levels were evaluated in populations with variable on-treatment low-density lipoprotein cholesterol (LDLC) </≥70 mg/dL and C-reactive protein </≥2 mg/L and in patients with or without diabetes mellitus. On-treatment non-HDLC levels linearly associated with ΔPAV. Overt PAV progression (ΔPAV>0) was associated with achieved TG levels >200 mg/dL, respectively. Lower on-treatment non-HDLC and TG levels associated with significant PAV regression compared with higher non-HDLC and TG levels across all levels of LDLC and C-reactive protein and irrespective of diabetic status ( P <0.001 across all comparisons). ΔPAV were more strongly influenced by changes in non-HDLC (β=0.62; P <0.001) compared with changes in LDLC (β=0.51; P <0.001). Kaplan–Meier sensitivity analyses demonstrated significantly greater major adverse cardiovascular event rates in those with higher versus lower non-HDLC and TG levels, with an earlier separation of the non-HDLC compared with the LDLC curve. Conclusions—: Achieved non-HDLC levels seem more closely associated with coronary atheroma progression than LDLC. Plaque progression associates with achieved TGs, but only above levels of 200 mg/dL. These observations support a more prominent role for non-HDLC (and possibly TG) lowering in combating residual cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of TRLs and remnant lipoproteins contribute directly to atherosclerosis by promoting endothelial dysfunction, inflammation, and foam cell formation [8, 9].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genetic studies and epidemiologic data increasingly implicate remnant lipoproteins as causal contributors to atherogenesis, providing a strong mechanistic and clinical rationale for targeted intervention [8–12].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“However, clinical trials testing the efficacy of TG-lowering strategies have largely been negative.(26,27) This may be in part”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B. R., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–142 of 142
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 6
New joint consensus initiative on quantifying atherogenic lipoproteins
Stock, J. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.037 · Cited by 4
Dron, J. S., Lazarte, J., & Hegele, R. A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311581 · Cited by 4
Hubacek, J. A., Nikitin, Y., Ragino, Y., Stakhneva, E. M., Pikhart, H., Peasey, A., Holmes, M. V., Stefler, D., Ryabikov, A., Verevkin, E., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260229 · Cited by 4
“This is consistent with the recent suggestions that serum TG and TG-rich remnant particles and non-HDL-C might be more powerful for predicting CVD and total mortality than TC or LDL-C [37].”
ResultBogdanov, D. Y., Афанасьевна, Н. В., & Shestopalov, E. Y. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3128 · Cited by 4
Gut permeability is associated with lower insulin sensitivity in youth with perinatally acquired HIV
Dirajlal‐Fargo, S., Yu, W., Jacobson, D. L., Mirza, A., Geffner, M. E., Jao, J. K., McComsey, G. A., & (PHACS), F. T. P. H. C. S. (2024) · AIDS · doi:10.1097/qad.0000000000003896 · Cited by 4
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
Gao, W., Zhu, R., She, J., Huang, R. H., Cai, L., Jin, S., Lin, Y., Lin, J., Chen, X., & Chen, L. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1567348 · Cited by 3
“…determinant of culprit lesion plaque burden in acute coronary syndrome (19), directly correlating with the necrotic core volume of atherosclerotic plaques and exhibiting a stronger association with the progression of coronary atherosclerosis compared to low-density lipoprotein cholesterol (19, 20).”
Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients
Clark, D., Puri, R., & Nissen, S. E. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1833716 · Cited by 3
Self-citationLevinson, S. S. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae125 · Cited by 2
Miao, C., Ye, X., Zhang, W., Sheng, C., Huang, Q., & Wang, J. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.08.007 · Cited by 2
LIpid Response to Statins ± Ezetimibe In Mumbai (LIRIM): A Cross-sectional Observational Study
Shah, V. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0622 · Cited by 1
Xie, H., Li, J., Shen, L., Yu, P., Wang, S., Xiaohu, C. H. E. N., & Shuhua, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1739961 · Cited by 1
Honicky, M., Cardoso, S. M., de Lima, L. R. A., Vieira, F. G. K., Back, I. D. C., & Moreno, Y. M. F. (2026) · Pediatric Cardiology · doi:10.1007/s00246-026-04295-z · Cited by 1
Novel Biomarkers at Risk Stratification of Diabetes Mellitus Patients
Berezin, A. Е. (2017) · Stem cells in clinical applications · doi:10.1007/978-3-319-55687-1_6 · Cited by 1
Chan, P., Shao, L., Tomlinson, B., & Liu, Z.-M. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.10.26 · Cited by 1
“Non-HDL-C levels provide better prediction of ASCVD events than LDL-C levels in statin-treated patients (4) and in an analysis of changes in atheroma volume determined by coronary intravascular ultrasonography, the achieved non-HDL-C levels were more closely associated with coronary atheroma progression than LDL-C lev…”
BackgroundDiagnóstico de la dislipidemia aterogénica por los médicos de atención primaria en España
Álvarez, J. C., Rodríguez, Á. D., Rodríguez, E. M., García, N. C., Estrada, C. C., & Calvo, J. A. S. (2020) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2020.07.008 · Cited by 1
Nozue, T. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed239 · Cited by 1
“In a clinical study using intravascular ultrasound, a higher TG level was associated with a greater increase in plaque volume in patients with CAD 4) .”
Kunwar, B., Jain, V., & Verma, S. K. (2023) · Pharmacologia · doi:10.17311/pharmacologia.2023.21.28 · Cited by 1
Cardiovascular Risk Assessment in the Immediate Postoperative Period of Bariatric Surgery
Bratti, L. D. O. S., Martins, A. C., Nunes, B. F., Moura, E. Q. D. A., de Moraes, A. C. R., & Filippin-Monteiro, F. B. (2025) · Obesities · doi:10.3390/obesities5010005 · Cited by 1
Филимонов, Е. С., Кorotenko, O. Y., Rumpel, O. A., & Блажина, О. Н. (2020) · Russian Journal of Occupational Health and Industrial Ecology · doi:10.31089/1026-9428-2020-60-3-157-161 · Cited by 1
Ji, X., Jin, S., Wang, Y., Chen, Y., & Zhang, J. (2021) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2021.0032 · Cited by 1
Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering
Kataoka, Y., Andres, J., Puri, R., Psaltis, P. J., & Nicholls, S. J. (2016) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.22.034
Self-citationLow-Density Lipoprotein Measurement Discordance
Intwala, S., Stone, N. J., & Balady, G. J. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0256
High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?
Nelson, A. J., Mirzaee, S., & Nicholls, S. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00363-3
Self-citationROLE OF NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN CEREBROVASCULAR ACCIDENTS
Sechassayana, N. (2019) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2019/452
Korolyuk, O. Y. (2020) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs05.01.125
da Silva, P. M., Duarte, J. S., HAFE, P. V., Gil, V. M., de Oliveira, J. N., & de Sousa, G. (2018) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2017.07.004
Determination of Small and Dense of Low-Density Lipoprotein and Coronary Heart Disease
李, 国. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.118514
Impact of Dyslipidemia on Ischemic Stroke
Kim, Y., & Kim, E. G. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_3
Frolov, M. Y., Salasyuk, A. S., & Rogov, V. A. (2021) · Kardiologiia · doi:10.18087/cardio.2021.10.n1722
Rosine, B. T., Ntchapda, F., & Miaffo, D. (2022) · Journal of Pharmaceutical and Biological Sciences · doi:10.18231/j.jpbs.2022.006
Non-high-density lipoprotein cholesterol and treatment targets in vascular surgery patients
Braet, D. J., Pourak, K., Mouli, V. H., Palmon, I., Dinh, D., Osborne, N. H., Vemuri, C., & Brandt, E. J. (2022) · Vascular · doi:10.1177/17085381221126232
“15 Non-HDL is a better marker for risk of coronary artery disease and is more closely associated with coronary atheroma progression than LDL. 12,15,16 Furthermore, non-HDL has been shown to be a reliable predictor of adverse cardiovascular outcomes amongst patients on lipid-lowering therapy and to…”
BackgroundWhy Non-HDL Cholesterol is Preferred over Apolipoprotein B-100 (Apo B)Preprint
Levinson, S. S. (2023) · doi:10.32388/tulata
Vitamin D deficiency and metabolic syndrome—Is there a causality?
Garg, M. K., & Mittal, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00024-4
Song, Y., Dang, Y., Feng, J., & Ruan, L. T. (2024) · Cardiology Research · doi:10.14740/cr1634 · Cited by 1
“Puri et al also found that the non-HDL-C concentration was strongly associated with the progression and regression of coronary atherosclerotic plaque volume, but not with LDL-C concentration [29].”
BackgroundAkkaya, S., & Özen, K. (2024) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.1552487
Mahmeed, W. M. A., Al-Kindi, M., Al-sarraf, A., Amin, H., Zirie, M. A., Alawadi, F., Sabbour, H. M., Al-Waili, K., Lessan, N. G., Tikriti, A. A., et al. (2026) · Angiology · doi:10.1177/00033197261422789
He, Z., Lv, M., Luo, J., Li, Q., Zhang, Z., & Niu, X. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1865857
“This underscores the importance of lowering non-HDL cholesterol levels in the primary prevention of stroke (34).”
Non-HDL Cholesterol as a Predictor of Coronary Atherosclerosis in South Asians: A Narrative Review
Yaligar, A., Ramachandran, S. P., Kulkarni, A., & Kalra, D. K. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01468-2
“Lastly, coronary atherosclerotic plaque progression as measured by IVUS was more closely associated with non-HDL-C than LDL-C [ 44].”
Metadata
- Authors
- Puri, R., Nissen, S. E., Shao, M., Elshazly, M. B., Kataoka, Y., Kapadia, S. R., Tuzcu, E. M., & Nicholls, S. J.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2016-11
- Volume
- 36
- Issue
- 11
- Pages
- 2220-2228
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2509381650
- Cited by
- 143
- References
- 46
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 17 · 2023: 18 · 2022: 8 · 2021: 11 · 2020: 17 · 2019: 24 · 2018: 20 · 2017: 14 · 2016: 3
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Sanofi
- Cleveland Clinic
- InfraRedx
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- non-HDL cholesterol, triglycerides, atherosclerosis progression, LDL cholesterol, triglyceride-rich lipoproteins, residual cardiovascular risk, major adverse cardiovascular events, intravascular ultrasound, coronary artery disease, diabetes mellitus, C-reactive protein
- MeSH terms
- Aged, Hypolipidemic Agents, Cholesterol, Clinical Trials as Topic, Coronary Artery Disease, Coronary Vessels, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Risk Factors, Time Factors, Triglycerides, Biomarkers, Multivariate Analysis, Linear Models, Treatment Outcome, Ultrasonography, Interventional, Disease Progression, Kaplan-Meier Estimate, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
